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ABSTRACT
This is a fatal case of fungaemia due to Cryptococcus albidus in an elderly woman with 
type 2 diabetes mellitus who presented pleural effusion as the only clinical presentation. Not 
only infections of the pleura are uncommon presentations of pulmonary cryptococcosis, but 
these infections due to non-C. neoformans species are extremely rare. This report places 
C. albidus on the growing number of disseminated mycosis-causing agents in diabetic patients.
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INTRODUCTION
Cryptococcosis is an important opportunistic fungal infection that in the vast 
majority of cases is caused by Cryptococcus neoformans, a basidiomycetous 
encapsulated yeast that lives in diverse environmental niches. This mycosis, 
which is initially established in the respiratory tract after the inhalation of fungal 
cells (likely desiccated yeast or spores), presents most frequently as meningitis or 
meningoencephalitis, predominantly among HIV patients1. However, cryptococcosis 
can affect any tissue or organ of the human body and the risk of severe invasive 
or disseminated disease increases if the infection is left untreated and is highly 
dependent on the degree of immunosuppression of the patient2. To our knowledge, 
this report is the first to describe a fatal case of cryptococcemia, with pleural effusion 
as the only presentation, caused by a non-C. neoformans species, Cryptococcus 
albidus, in a non-HIV, but chronically ill, elderly female patient from Colombia. 
This case emphasizes the increasing risk for immunocompromised patients and 
those with underlying conditions, such as diabetes, to acquire systemic mycoses 
due to infrequent environmental pathogens.
CASE REPORT
An 85-year old woman with type 2 diabetes mellitus (T2DM) and arterial 
hypertension was admitted to a secondary-level hospital in Bogota on October 
2, 2017 (day 0) with hyperglicemia. The patient presented with fatigue, polyuria, 
polydipsia and nocturia. On day 4, the patient had an altered state of consciousness 
and an episode of atrial fibrillation, which was assessed and reversed. Since there was 
a risk of central nervous system (CNS) thrombosis, anticoagulation was prescribed. 
A computed tomography (CT) scan of the head showed an old lacunar infarction on 
the left superior cerebellar artery and chronic ischemic microangiopathy. On day 7, 
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hypoxia (85%) and another episode of atrial fibrillation 
occurred. Chest radiography showed opacification of the 
left hemithorax, the cardiac silhouette was not visible and 
prominent pulmonary hilar vessels with atelectasis on the 
right apical lobe were observed. Considering the size of the 
pleural effusion, the patient’s condition and the associated 
risks, on day 8, the patient was referred to an intermediate 
care unit in a tertiary-level hospital, in the same city.
On day 9, the blood count showed decreased number 
of erythrocytes (2.54 million cells/μL) with low hematocrit 
(23.7%) and hemoglobin (8.6 g/dL). Platelets and leukocytes 
counts were normal, although there was an increased 
percentage of neutrophils (78%). The blood chemistry 
revealed normal levels of electrolytes, blood urea nitrogen 
and creatinine. On the same day, a closed tube thoracostomy 
was conducted and 2,500 mL of pleural fluid, of bloody 
appearance, were drained. The pleural fluid had normal pH, 
glucose and albumin, with low protein (1.9 g/L) and high 
lactate dehydrogenase (2,437 IU/L). The leukocyte count 
was very low (23 cells/mL) with 80% polymorphonuclear 
and 20% mononuclear cells. The erythrocyte count was 
elevated (13,498 cells/μL) with 95% biconcave and 
5% crenated cells. Altogether, the characteristics of the 
pleural fluid suggested an inflammatory process. No 
microorganisms were observed with Gram and Ziehl-
Neelsen staining of the pleural fluid. PCR for mycobacteria 
and cultures for bacteria and fungi of the pleural fluid were 
negative. India ink was not performed on the pleural fluid 
as there was not suspicion of cryptococcal infection.
On day 12, the patient was transferred to a general 
ward. Two days later, chest and abdominal CT scans 
confirmed the pleural effusion on the left side (Figure 1) 
and showed an abdominal mass and renal atrophy on the 
left kidney, suggesting a metastatic pleural neoplasm. 
Blood cultures were performed and pleural biopsies 
were taken on days 16 and 18, respectively. However, 
the patient’s condition deteriorated, and the woman died 
after 21 days of hospitalization. Pleural biopsies reported 
a chronic nonspecific pleuritis. Cryptococcus albidus was 
recovered from the blood culture. The isolate was identified 
by the VITEK®2 YST ID card (bioMérieux, France) and 
confirmed by MALDI-TOF mass spectrometry with the 
MYLA® software (VITEK® MS, bioMérieux, France), 
with an acceptable confidence value of 99.9%. Thus, 
cryptococcemia was diagnosed.
DISCUSSION
This report presents a case of lethal fungaemia, with 
involvement of the pleura, caused by a non-C. neoformans 
cryptococcal species, an extremely rare presentation, whose 
diagnosis can be easily delayed or mistaken. As the lungs 
are the primary target organs of cryptococcal species, 
pulmonary disease is still an important infection that may 
be underdiagnosed due to the nonspecific symptoms and 
broadly categorized findings. Predisposing factors such 
as hematologic malignancies, lung cancer, solid organ 
transplantation, diabetes mellitus, glucocorticosteroid 
use, and hepatic cirrhosis increase the risk for developing 
pulmonary cryptococcosis, which may manifest as 
pulmonary nodules, masses or infiltrates, mediastinal 
lymphadenopathy or less frequently pleural effusions3. 
However, in a recent review, only 50 cases of pleural 
effusion, as a manifestation of pulmonary cryptococcosis, 
have been reported4. Even rarer are cryptococcal infections 
of the pleura caused by non-C. neoformans species. 
Nonetheless, this number may be underestimated because 
in many cases, as occurred in the case described herein, 
cultures from the pleural fluid are generally negative 
for Cryptococcus spp., making diagnosis even more 
challenging. Additionally, direct microscopy to observe 
yeast-like cells in the pleural fluid is not always possible, 
due mainly to the small amount of microorganisms present 
in the fluid5,6. 
Similarly to C. neoformans and its sibling species C. gattii, 
the main etiological agents of cryptococcosis, C. albidus is a 
free-living encapsulated yeast that resides in the environment 
and whose clinical relevance remains unknown7, though 
with an incremental rise in the number of at-risk patients, 
the incidence of infections due to non-C. neoformans/
non C. gattii species have also increased, with C. albidus 
Figure 1 - Computed tomography scan of the chest showing a 
massive left-side pleural effusion with a compressive atelectasis 
in the right apical lobe (arrow).
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and C. laurentii accounting for 80% of reported cases8-10. 
Among the few cases of cryptococcal infection involving 
the pleural space, only one has been reported to be caused 
by C. albidus, although concomitantly with mucormycosis 
and in a patient undergoing hemodialysis11. Particularly for 
C. albidus, bloodstream and CNS are the commonest sites of 
infection8,12. In addition, until now in Colombia, C. albidus 
has not been reported as a causative agent of disease and 
its isolation from environmental sources has been rather 
sporadic13,14.
While in many patients without predisposing condition, 
pleural effusion presents only as localized disease6,15, in the 
current case, positive blood culture for C. albidus indicated 
that the pleural effusion has possibly led to the dissemination 
of the microorganism. This case of an elderly woman who 
succumbed due to cryptococcal pleuritis highlights the 
importance of considering not only the risk factors of the 
patients, but also the emergence of new pathogens, requiring 
an appropriate and prompt diagnosis. In comparison with 
other cases of cryptococcal pleural infection, the case 
reported here was difficult to diagnose because of the variety 
of general signs and symptoms of the patient, her chronic 
condition of T2DM and advanced age. Initially, pleural 
tuberculosis was considered, then, the bloody appearance 
of the pleural fluid suggested metastatic pleural neoplasms 
or metastatic malignancies, and the onset of neurological 
symptoms also biased the diagnosis. Only post-mortem, 
fungaemia and disseminated cryptococcosis were diagnosed. 
Even though C. albidus was correctly identified, 
its identification was only possible with automatized 
methodologies, namely VITEK®2 YST ID system and 
MALDI-TOF MS. Morphologically and physiologically, 
species within the genus Cryptococcus are very easily 
mistaken, for instance, serotyping of some C. albidus 
strains leads to grouping them as C. neoformans, serotype 
A strains7. However, C. neoformans differs from C. albidus 
by the activity of the phenoloxidase enzyme that allows it 
to synthesizemelanin. Growth of brown to black pigmented 
colonies on specific media allows the differentiation of 
C. neoformans and C. gattii, from other yeasts of the genus, 
including C. albidus. C. albidus does not produce melanin 
due to the lack of phenoloxidase activity7, which helps the 
diagnosis (Figure 2).
To conclude, this case emphasizes the importance of 
considering atypical infections like cryptococcal infection 
of the pleura in the differential diagnosis of patients with 
pleural effusion. In addition, it underlines the capacity 
of C. albidus to cause disseminated disease, which is 
uncommon, but is a very serious condition that should be 
deemed possible in diabetic patients and in the elderly and 
critically ill individuals. As reported here, the non-specific 
clinical features of pulmonary disease can hinder an 
opportune treatment, leading to an increased morbidity 
and even in some cases increased mortality rates. Thus, 
the correct and prompt identification and the surveillance 
of non-prevalent fungal species, such as C. albidus, causing 
disease in chronically ill individuals, will aid determining 
the real impact of these atypical fungi as etiologic agents 
of disseminated diseases. Additionally, the surveillance 
of antifungal susceptibility of emerging pathogens is 
recommended to help choosing specific management 
for individual patients, considering that species like 
C. albidus are less susceptible or even resistant to azoles7, 
one of the most commonly used drugs for the treatment of 
cryptococcosis and other mycoses. C. albidus must be then 
added to the growing number of recently described causative 
agents of disseminated mycoses in diabetic patients.
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Figure 2 - Cryptococcus albidus (A) and Cryptococcus 
neoformans (B) grown in Niger seed agar. C. albidus colonies 
grow cream-colored, while C. neoformans colonies produce 
melanin, due to the phenoloxidase activity, and turn brown.
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